Additionally, there are studies that have assessed the effectiveness and safety of combining the tyrosine kinase inhibitor cabozantinib with a PD-L1 inhibitor in patients with advanced colorectal cancer within a specific colorectal cancer population. The gene discussed is CD274; the disease is colorectal cancer.